AbbVie Aktie
WKN DE: A1J84E / ISIN: US00287Y1091
09.12.2024 14:50:55
|
AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal
(RTTNews) - AbbVie Inc. (ABBV) Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal.
In the study, patients treated with tavapadon experienced a statistically significant improvement in MDS-UPDRS Parts II and III combined score, a tool to measure the severity and progression of Parkinson disease, compared to those on placebo.
The company said it is on track to submit the New Drug Application to the Food & Drug Administration (FDA) in 2025.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbbVie Incmehr Nachrichten
Analysen zu AbbVie Incmehr Analysen
Aktien in diesem Artikel
AbbVie Inc | 187,80 | 0,11% |
|